Necrobiotic xanthogranuloma (NXG) is a rare inflammatory histiocytic disease of the skin. Xanthogranuloma of the central nervous system is rare and few cases have been reported. To the authors' knowledge, there has been no previously reported case of NXG in which an intracranial lesion was found. This 52-year-old man, in whom NXG with all its cutaneous manifestations had been diagnosed, presented with three episodes of generalized tonic-clonic seizures. A contrast-enhanced computerized tomography scan of his brain revealed a bifrontal, dura-based mass lesion. The lesion was excised and reported to be an NXG that was similar, but not identical to the skin lesions. The patient was placed on a regimen of antiepileptic drug and chlorambucil after surgery.

Download full-text PDF

Source
http://dx.doi.org/10.3171/jns.2004.100.6.1111DOI Listing

Publication Analysis

Top Keywords

necrobiotic xanthogranuloma
8
xanthogranuloma cutaneous
4
cutaneous cerebral
4
cerebral manifestations
4
manifestations case
4
case report
4
report review
4
review literature
4
literature necrobiotic
4
nxg
4

Similar Publications

Foamy Cell Angiosarcoma Resembling a Xanthomatous Histiocytic Infiltrate Without Evidence of Vascular Malignancy.

J Cutan Pathol

December 2024

Department of Medicine, Division of Dermatology, St. Louis School of Medicine, Washington University, St. Louis, Missouri, USA.

Angiosarcoma is a rare and aggressive malignancy of endothelial cells with multiple subtypes. Foamy cell angiosarcoma is a rare variant in which endothelial cells demonstrate "foamy" cytoplasmic change. We present the case of a 59-year-old male who presented with progressive erythema and swelling of the midface and bilateral eyelids.

View Article and Find Full Text PDF
Article Synopsis
  • Intravenous immunoglobulin (IVIG) therapy shows promise for treating various dermatological autoimmune diseases due to its ability to modulate the immune system and low risk of severe side effects.
  • The exact mechanism of how IVIG works in autoimmune diseases is still debated, but it involves neutralizing harmful autoantibodies and preventing tissue damage.
  • While IVIG is primarily used off-label for conditions like dermatomyositis and systemic sclerosis, a key study (ProDERM 2022) demonstrated its effectiveness specifically for dermatomyositis, and it is commonly used as first-line treatment for scleromyxedema.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!